PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024

Rhea-AI Summary

PROCEPT BioRobotics (Nasdaq: PRCT), a surgical robotics company specializing in urology solutions, has announced its plans to release second quarter 2024 financial results on August 1, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results.

Interested parties can access the call via a webcast link or dial-in registration for sell-side analysts. The live audio webcast and an archived recording will be available on the company's investor relations website. The webcast replay will be accessible for at least 90 days after the event.

SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

• Webcast link for interested listeners:
  • https://edge.media-server.com/mmc/p/qsztnzfu/

• Dial-in registration for sell-side research analysts:
  • https://register.vevent.com/register/BI7bf6aa315a2b44d6a070a16b6608b822

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com.

An archived recording will be available on the “Investors” section of the Company’s website at: https://ir.procept-biorobotics.com. Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@PROCEPT-BioRobotics.com

FAQ

When will PROCEPT BioRobotics (PRCT) report its Q2 2024 financial results?

PROCEPT BioRobotics (PRCT) will report its second quarter 2024 financial results on August 1, 2024, after market close.

What time is PROCEPT BioRobotics' (PRCT) Q2 2024 earnings call scheduled for?

PROCEPT BioRobotics' (PRCT) Q2 2024 earnings conference call is scheduled for August 1, 2024, at 4:30 p.m. Eastern Time.

How can investors access PROCEPT BioRobotics' (PRCT) Q2 2024 earnings call?

Investors can access PROCEPT BioRobotics' (PRCT) Q2 2024 earnings call via a webcast link for listeners or a dial-in registration for sell-side research analysts, both available on the company's website.

Where can I find the replay of PROCEPT BioRobotics' (PRCT) Q2 2024 earnings call?

The replay of PROCEPT BioRobotics' (PRCT) Q2 2024 earnings call will be available on the 'Investors' section of the company's website at https://ir.procept-biorobotics.com for at least 90 days after the event.